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The ketogenic diet in children 3 
years of age or younger: a 10-year 
single-center experience
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The ketogenic diet (KD) is an effective treatment option for intractable epilepsy. Here, we reviewed 
the last 10 years of our experience with the KD and characterized its use in patients under 3 years 
of age. Medical records of all patients under the age of 3 years who were treated with the ketogenic 
diet from April 2004 to June 2014 were retrospectively reviewed. One hundred and nine patients with 
drug-resistant epilepsy were included. The mean age at the initiation of the KD was 1.4 ± 0.8 years 
old. The youngest patient was 3 weeks old. After 3 months, 39% (42/109) of patients responded to 
the KD and experienced more than 50% seizure reduction. Of those 42 patients, 20 (18%) achieved 
complete seizure control. Patients with a genetic etiology showed a better response to the KD in seizure 
reduction than the other patients (p = 0.03). Age at initiation of the KD was not related to eventual 
seizure outcome (p = 0.6). The KD continues to be an effective, safe, and well tolerated treatment 
option for infants with intractable epilepsy.
The ketogenic diet (KD) is a high fat, low carbohydrate, and protein restricted diet that is rigorously med-
ically supervised and widely recognized as an effective treatment option for intractable epilepsy. It’s use in 
the United States dates to the 1920s, when Woodyatt and Wilder independently described the production of 
beta-hydroxybutyric acid or ketonemia via dietary manipulation other than fasting1,2.
In a randomized controlled trial analyzing 103 children of varying ages, seizure types, and epilepsy syndromes, 
38% of children treated with the KD after 3 months had greater than 50% seizure reduction compared with 6% 
of controls using heterogeneous anticonvulsant therapies. 7% in the diet group had greater than 90% seizure 
reduction compared with none of the controls3. Overall, while the KD’s use as a therapy for infantile spasms (IS) is 
perhaps the best known and investigated4–7, its effectiveness, safety, and tolerability for infantile onset intractable 
epilepsy regardless of seizure type has started to be elaborated7–9. A recent survey of health care professionals on 
the use of the ketogenic diet updated the long held notion that it was a therapy of “last resort.” Within sub-types of 
infantile onset epilepsy, it was considered the first or second treatment for glucose transporter protein 1 deficiency 
(GLUT1) (86%) and third or fourth for Dravet (63%) and West (71%) syndromes10. Despite this, various aspects 
of implementation and utility of the KD in infants remain less completely understood, including: predictors of 
favorable response, the combined use of extracted breast milk, potential adverse events, reasons for early with-
drawal, as well as the diet’s efficacy in management of specific epilepsy syndromes and etiologies. How advances 
in medical genomics and the burgeoning identification of causative gene mutations in epilepsy might eventually 
apply to the ketogenic diet is of considerable interest.
The ketogenic diet has been in continued use at Children’s Memorial Hospital (renamed Ann & Robert H. 
Lurie Children’s Hospital of Chicago) since 196311. In this study, we retrospectively reviewed the last 10 years 
of our experience with the KD and characterized its use in patients under 3 years of age. Our goals were to (1) 
identify predictors of favorable outcome, (2) investigate reasons for early withdrawal with relation to age, diet 
formulation, or adverse events, and (3) to evaluate efficacy with specific regard to epilepsy syndrome or etiology, 
utilizing genetic diagnoses if available.
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Methods
Information regarding patient demographics, seizure types, seizure frequency, epilepsy syndrome, etiology, 
MRI findings and electroencephalogram findings was retrospectively abstracted from the medical records of all 
patients under the age of 3 years who were treated with the ketogenic diet from April 2004 to June 2014 at the 
Lurie Children’s (formerly Children’s Memorial Hospital). All patients had medically intractable epilepsy, defined 
as persistent seizures despite the use of two or more appropriate anticonvulsants at therapeutic doses.
Early withdrawal and early discontinuation were defined as cessation of the KD before 3 months of treatment 
had elapsed. In our analysis, we considered early withdrawal, early discontinuation, and non-adherence in aggre-
gate. Patients were then categorized into two groups: (1) an early withdrawal group and (2) an adherent group 
(Fig. 1). To determine the reasons for early withdrawal, three clinical features were reviewed: very short-term 
efficacy of the KD, adverse events, and the implementation and practice of the KD. The number of patients who 
withdrew from the diet early because of ineffectiveness was calculated.
Further, the patients who completed 3 months on the KD were categorized into four groups based on the 
percentage of seizure reduction at 3 months: (1) complete seizure control, (2) >90% improvement, (3) 50–90% 
improvement, and (4) <50% improvement. Responders were defined as those who experienced >50% seizure 
reduction. Non-responders were defined as those who had <50% seizure reduction. Seizure frequency was 
reported by the parents as well as by EEGs when available. We defined adverse events broadly, including both new 
clinical symptomatology and lab abnormalities that started while using the KD. Events that prompted early with-
drawal were also specified. To evaluate the practice details of KD implementation and maintenance, we assessed 
the ratio (grams of fat to grams of carbohydrate + protein) used, the method of food consumption, and the type 
of food that was consumed. Finally, in order to elucidate any age-dependent outcomes, patients were further cat-
egorized into three groups based on their age at the KD initiation and evaluated as follows: (1) patients <1 year 
old, (2) 1–2 years old, and (3) >2 years old. The study was approved by the Lurie Children’s Hospital Institutional 
Review Board. All research was performed in accordance with relevant guidelines/regulations and a waiver of 
informed consent was granted for this retrospective study.
The KD protocol. Before initiation of the KD, a multidisciplinary evaluation was performed by two reg-
istered dietitians, advanced practice nurses, and by a licensed clinical social worker. During the visit, a review 
of the medical history was obtained, diet protocols and lifestyle implications were discussed, and a neurologic 
examination was completed. After this preliminary visit, one of the following combinations of food consumption 
mechanism and food type were selected: oral liquid, tube-fed liquid, oral solids, or a combination of oral liquid 
and solid foods. Liquid foods included: individually designed meals with oils as well as commercial formulas 
including KetoCal® (Nutricia Inc., Gaithersburg, MD, U.S.A.) and Ross Carbohydrate Free® Soy Formula Base 
With Iron (Abbott Nutrition, Columbus, OH, USA). Individual calorie and protein amounts were calculated by 
our dietitians based on age-dependent standard daily requirements, baseline weight and height, level of activity, 
and the pre-diet intake evaluation. Supplementation with vitamins and minerals was provided based on individ-
ual patients’ needs and food types used. The KD was initiated at a ratio of 1:1 (fat grams: carbohydrate + protein 
grams) without a fast as an inpatient in the hospital. The keto ratio was increased daily, reaching up to 3:1 on 
day 3. On day 4, patients were discharged home at the ratio of 3:1 with full calories. Fluids were not restricted. 
Patients were then evaluated by our multidisciplinary KD team 1 month later and then every 3 months thereafter. 
Intermittent outpatient adjustments of diet ratio, number of calories, and amount of protein were made to maxi-
mize seizure control, minimize side effects, and maintain appropriate growth.
Statistical analysis. In order to determine the factors that were associated with the early withdrawal of the 
KD, we compared the clinical variables between the early withdrawal group and the continuing (adherent) group. 
We used the independent t-test or the Mann-Whitney U test to analyze continuous variables including the age at 
KD initiation, age at seizure onset, seizure onset prior to the KD initiation, duration of the KD, and the number 
of prior antiepileptic drugs. For categorical data, Pearson’s chi-square test for independence of rows and columns 
was used. P values < 0.05 were regarded as statistically significant. Statistical analyses were performed using SPSS 
version 22 (SPSS Inc., Chicago, IL, USA). Data are expressed as number (%), mean ± standard deviation, or 
median (interquartile range (IQR)).
Figure 1. Chart showing the use of the KD in patients under 3 years old in each year (From April 2004 to June 
2014). (N. of patients in each year).
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Results
Baseline characteristics. One hundred and eleven patients under 3 years of age were started on the KD 
(Fig. 1). Two patients were excluded from the study: one underwent epilepsy surgery after one month of the 
treatment with the KD; the other, a patient with early myoclonic encephalopathy (EME), died due to respiratory 
failure 2 months into treatment with the KD. Ultimately, one hundred and nine patients with drug-resistant 
epilepsy were included for analysis (Fig. 2). Details of baseline patient characteristics are given in Table 1. The 
median age at seizure onset was 4 (IQR 1–6) months of age. The median number of previously attempted and/or 
concomitantly used medications at the time of the KD initiation was 4 (IQR 3–5). Approximately half (56%) of 
the patients had West syndrome. The EEG was abnormal in all patients at initiation of the diet.
The mean age at the initiation of the KD was 1.4 ± 0.8 years old. The youngest patient was 3 weeks old. Among 
105 patients for whom information on the KD ratio was available, 20 were on a 3:1 ratio, 13 were on 3.5:1 and 59 
were on 4:1. Overall, 12 were on a ratio higher than 4:1. The maximum ratio used was 4.75:1. Every child reached 
a fat to non-fat ratio of 3:1 or higher except one who was on a ratio of 2.75:1. The form of the food that was 
used included solid foods (33%, 35/104), liquid foods (32%, 34/104) and a combination of both (33%, 35/104). 
[Among 69 patients who received a liquid form of the KD, 96% (66/69) utilized the ketogenic formula while 4% 
(3/69) were put on an individually designed liquid. Eight patients used expressed breast milk. The median dura-
tion of the KD was 1.1 (IQR 0.5–2.2) years. All but one patient had positive urine ketosis at some point during 
the diet. In the one outlier, the level of serum B-hydroxybutyrate was 1.32 mmol/L and seizures did not respond 
(seizure reduction <50%) to the 3 months of the diet therapy.
Efficacy. After 3 months, 39% (42/109) of patients responded to the KD and experienced more than 50% 
seizure reduction. Of those 42 patients, 20 (18%) achieved complete seizure control and an additional 3 (3%) 
experienced >90% seizure reduction (Table 1). There was no significant difference between age at the seizure 
onset (p = 0.2) or age at initiation of the KD (p = 0.5) between responders and non-responders. The number of 
previously or currently used anticonvulsants was lower among responders (p = 0.02).
Possibly due to the small numbers of patients, no specific etiology was significantly related to a positive 
response to the KD (Table 2). Interestingly, however, patients with a confirmed genetic mutation or a chromo-
somal abnormality showed a better response to the KD in seizure reduction than the other patients (p = 0.03). 
Genetic abnormalities were identified in 29 patients and included mutations of the following genes: BRAF, CDG 
1p, CDKL5, SCN1A, SCN2A, SCN8A, KCNQ2, DCX, EEF1A2, GFAP, GRIN2A, MTO, POLG, RARS2, TSC2, 
SLC35A2 and SLC6A8. Trisomy 21 was found in 5 patients. Microdeletions of chromosome 1, 6 and 16 were 
found in 5 patients. The KD was similarly effective in patients with diverse early onset epilepsies and in patients 
with West syndrome.
In general, there was no single EEG abnormality that was independently related to a favorable response to the 
KD. Among patients with focal slowing and spikes on the baseline EEG, the presence of electrodecrements was 
suggestive of a poor response, but failed to show a significant difference (p = 0.09).
Early withdrawal and associated factors. Only 12 of 109 patients (11%) withdrew from the diet before 
3 months. The most common cause for withdrawal was parental unhappiness with the diet’s rigidity (7/12). Only 
five patients stopped early either because of perceived ineffectiveness (3/12) or because of an adverse event (2/12) 
(Table 3). Young patients who were given ketogenic formula with or without solids were more likely to continue 
the diet (p = 0.003). A high KD ratio (≥4:1), the use of feeding tube or the use of expressed breast milk was not 
related to early KD withdrawal. Young patients who were given ketogenic formula were more likely to continue 
the diet (p = 0.003). A high KD ratio (≥4:1), the use of feeding tube or the use of expressed breast milk was not 
related to early KD withdrawal.
Young patients who were given ketogenic formula were more likely to continue the diet (p = 0.003). A high KD 
ratio (≥4:1), the use of feeding tube or the use of expressed breast milk was not related to early KD withdrawal.
Figure 2. Flow diagram.
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The two adverse events that caused early withdrawal were behavioral food refusal and persistent acidosis in 
the setting of poor food intake. No one specific adverse event occurred more frequently among the early with-
drawals. Constipation was more likely to be reported in the adherent group who were on the diet for a longer 
period of time (p = 0.009). Further details of the adverse events are provided in Table 4.
The effects of age. Age at initiation of the KD was not related to eventual seizure outcome (p = 0.6). 
Likewise, age was not related to early withdrawal from the KD (p = 0.2). Interestingly, however, the age group 
most likely to withdraw from the KD early was group 2 (patients between 1 and 2 years old) (7/12, 58%). This 
group also showed a wider variety of food types used during the KD compared to the other two groups whose 
food options were more selective. As would be expected, formula was used more in younger patients (<1 year 
old), In older patients (>2 years old), solid foods were more predominantly used. In patients between 1 and 
2 years old, no single predominant food type was found (p < 0.0001). Details are given in Table 5. The overall 
occurrence of an adverse event was not related to age (p = 0.6). Patients who started the KD earlier (before 2 years 
old), however, were more likely to report constipation (p = 0.005). Kidney stones were observed only in patients 
younger than 1, but the difference according to age was not statistically significant (p = 0.07). Patients who dis-
continued the KD early because of an adverse event were 1.9 and 2.6 years old at the time of the KD initiation.
Discussion
Within a span of 10 years at our center, more than 100 patients were initiated on the KD before they turned 3 
years old. Overall, 20% of patients became seizure free and many (39%) experienced a significant seizure reduc-
tion (>50%) after the initial 3-months of the KD therapy. This trend is similar to what other studies have reported 
for older children, in which 27–38% of children have a >50% seizure reduction after 3 months3,12. The results 
Values
Males/Females, n 50/59
Age at the seizure onset, median (IQR), y 0.3 (0.1–0.5)
Age at the initiation of the KD, mean ± SD, y 1.4 ± 0.8
Duration of the KD, median (IQR), y 1.1 (0.5–2.2)
N of prior anticonvulsants, median (IQR) 4 (3–5)
Epilepsy syndrome, n(%)
West syndrome 61 (56)
Dravet syndrome 9 (8)
Localization related epilepsy 7 (6)
LIEE 5 (5)
EIEE/EME 3 (3)
Doose syndrome 2 (2)
Myoclonic epilepsy 2 (2)
MMPI 1 (1)
Unknown 19 (18)
Etiology, n(%)
Structural 24 (22)
Perinatal events (HIE or IVH) 20 (18)
Genetic (chromosomal abnormalities or single gene defect) 14 (13)
Channelopathy 13 (12)
Metabolic disorder 8 (7)
Leukodystrophy 4 (4)
Trauma 3 (3)
Unknown 23 (21)
EEG findings, n(%)
Diffuse slowing with Mf spikes + electrodecrements 47 (43)
Diffuse slowing with Mf spikes 38 (35)
Focal slowing and spikes + electrodecrements 14 (13)
Focal slowing and spikes 9 (8)
Generalized spike wave discharges with no slowing 1 (1)
Outcome, n(%)
Seizure free 20 (18)
Reduction >90% 3 (3)
Reduction 50–90% 19 (17)
Reduction <50% 55 (50)
Withdrawal during the initial 3 months 12 (11)
Table 1. Patient characteristics (n = 109). KD, ketogenic diet; N, number; IQR, interquartile range; SD, 
standard deviation; LIEE, late infantile epileptic encephalopathy; EIEE, early infantile epileptic encephalopathy; 
EME, early myoclonic encephalopathy; MMFSI, malignant migrating focal seizures in infancy; HIE, hypoxic 
ischemic encephalopathy; IVH, intravenous hemorrhage; EEG, electroencephalogram.
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were also comparable to the rates of seizure reduction reported for the infants with West syndrome, which ranged 
from 39% to 67%4,6,13.
Our previous study was the first to investigate the role of the KD in infants with epilepsies other than West 
syndrome/infantile spasms7. Fifteen years ago, we had only a limited ability to assess the efficacy of the KD with 
etiologic specificity. Since then, there have been smaller studies and case series or case reports looking at the diet’s 
role in individual epilepsy syndromes or diseases that could include an infantile presentation, such as: GLUT-1 
deficiency syndrome, pyruvate dehydrogenase deficiency (PDHD), severe myoclonic epilepsy of infancy (Dravet 
syndrome), Rett syndrome, and selected mitochondrial disorders14–17. None of these studies, however, focused 
exclusively on early introduction of the KD during the time period of 3 years of age and younger. It is would be 
of great benefit to determine which epilepsy syndromes, beyond West syndrome, and which etiologies are more 
responsive to the KD, so as to promote early referral and initiation of treatment. In the present study, there was 
no significant difference between the effectiveness of the KD for patients with West syndrome and other epilepsy 
syndromes, which suggests that the KD should be considered early in all infants with refractory epilepsy once 
contraindications are ruled out.
Moreover, in our experience, a confirmed genetic abnormality was predictive of a good response to the KD. 
Nearly half of the patients with a confirmed genetic abnormality enjoyed a reduction in seizure frequency of 
>50%. A similar finding was described in a retrospective chart review of 64 consecutive patients with refractory 
epilepsy, children and adults, who were started on the KD at a tertiary epilepsy center18. This finding implies that 
the KD could also be considered by providers earlier, perhaps even before a patient fails two previous anticon-
vulsant medications, if he or she receives a positive genetic diagnosis. Furthermore, early diet initiation not only 
capitalizes on age-related ease of use and tolerability, but could also appeal to parents concerned about potential 
anticonvulsant side effects, a finding shared in other studies8,19.
In our experience with 109 children under 3 years of age, the KD was safely implemented and tolerated for 
the initial 3 months. Only about 10% of the children withdrew early. Among these, we found no critical adverse 
event related to use of the KD. The rate of early withdrawal was comparable to those reported in older children, 
which ranged from 12% to 163,12,20. A much higher number of early withdrawals have been reported in a study 
with adults. Implementation and maintenance of the KD was easier in young children whose diet habits are still 
flexible, a finding supported by previous studies with smaller sample sizes which found similarly low rates of early 
withdrawal in of children in this age group (<2 years old)4,5,7,13.
Responder Non-responder p-value
n 42 67
Age at the seizure onset, median (IQR), y 3 (2–6) 3 (1–3) 0.2
Age at the initiation of the KD, mean ± SD, y 1 ± 0.8 1 ± 0.8 0.5
N of prior anticonvulsants, median (IQR) 3 ± 1.6 4 ± 1.9 0.02
Risk factor
Positive MRI finding 20 34 0.7
Genetic abnormality 20 19 0.03
Metabolic abnormality 3 7 0.6
Etiology
Channelopathy 5 7 0.9
HIE or IVH 9 8 0.2
Leukodystrophy or Metabolic disorder 4 7 0.9
MCD or TS 6 17 0.2
Epilepsy syndrome
West syndrome 24 36 0.7
Non-West syndrome 18 31
EEG findings, n = 108
a. Diffuse slowing with Mf spikes 16 22 0.4
b. Diffuse slowing with Mf 
spikes + electrodecrements 18 29
c. Focal slowing and spikes 5 4
d. Focal slowing and 
spikes + electrodecrements 3 11
Table 2. Differences between responders (seizure reduction >50%) and the non-responders (seizure reduction 
<50%) on the ketogenic diet. KD, ketogenic diet; IQR, interquartile range; SD, standard deviation; N, number; 
MRI, magnetic resonance image; HIE, hypoxic ischemic encephalopathy; IVH, intravenous hemorrhage; MCD, 
malformation of cortical development; TS, tuberous sclerosis; Mf, multifocal.
Reason N (%)
Parental unhappiness 7 (6)
Ineffectiveness 3 (3)
Adverse event 2 (2)
Table 3. Reasons for early withdrawal (n = 109).
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Considering that this study was performed at a tertiary pediatric epilepsy center with a specialized KD team, it 
was surprising to find that parental dissatisfaction with the diet was the most commonly reported cause for early 
withdrawal. This finding emphasizes the extensive amount of multidisciplinary support that parents need while 
using the diet, especially during the complicated period of solid food introduction.
Adverse events were a rare cause of early withdrawal in children (2%), although many children experienced at 
least one during their 3 months use of the KD (63%, 69/109). This finding is in partial agreement with previous 
reports which described that approximately 30% of the children experience an adverse event, but only 3–5% of chil-
dren discontinue the diet due to adverse events4,5. We suspect that the reported rate of adverse events was higher in 
our study because our pre-determined threshold for adverse event reporting was intentionally set low. For instance, 
symptoms as mild as feeding difficulty or self-limited, small emesis were included as adverse events, which were in 
turn related to the fastidiousness of parental report or clinical judgement of the involved health care professional. 
Additionally, laboratory abnormalities such as decreased bicarbonate or glucose levels which were described in other 
studies but not reported as adverse events were counted as such in ours. We believe that the comprehensiveness of our 
reporting will be helpful in guiding physicians and caregivers when they plan to start the diet in infants and toddlers.
There was a significant relationship between early withdrawal from the diet and the food type that was used. 
While a few case-series and short studies have suggested improved tolerability of the liquid-based KD4,21–23, its use 
has never been studied exclusively in infants, the group that not only makes most frequent use of this formulation, 
but who may also benefit most from it. Our study demonstrates that a liquid-based KD with ketogenic formula 
can be used safely and effectively in infants and that it may even enhance patient and parental maintenance of the 
diet. We also report here on eight children who successfully completed the diet with a combination of formula 
and expressed breast milk. The use of breast milk was neither related to early withdrawal, nor to poor outcome in 
terms of seizure control. This finding suggests that consideration of ketogenic diet therapy should not reflexively 
prompt early weaning from breast milk.
We did not find any age-related difference in regard to the outcome or the practice of the KD therapy in young 
children. Some studies have suggested a young age at the time of the KD to be a favorable factor while others 
did7,20,24. In our study, age was not related to the seizure outcome but to the methods of the KD and to the adverse 
events. Younger ones (<1 year old) were more likely to be fed with the liquid KD food while older ones (>2 years 
old) were fed with the solid foods. Younger ones were more likely to report constipation and low carnitine levels 
compared to the older ones. Additionally, although we failed to see a statistically significant difference, we also 
saw an age-related trend in relation to early withdrawal. Interestingly, it was not the older children (>2 years old) 
or the younger ones (<1 year old), but the children who started the KD between 1 and 2 years old, who tended to 
withdraw early from the diet more frequently than the other two groups (p = 0.15). We hypothesize that applying 
the KD may be more challenging to children when they are being introduced to the solid foods for the first time. 
Total
Adherent 
group
Early withdrawal 
group p-value
N 109 97 12
Male/Female 50/59 44/53 6/6 0.8
Age at the initiation of the KD, mean ± SD, y 1.4 ± 0.8 1.4 ± 0.8 1.4 ± 0.8 1
N of prior anticonvulsants, n = 95 4 ± 1.9 4 ± 1.9 4 ± 1.8 0.7
Improved cognition, n = 95 47 47 0 0.007
High KD ratio ≥ 4:1 71 67 4 0.07
Food type, n = 104
Solid 35 28 7 0.1
Liquid 34 32 2
Solid and liquid 35 32 3
Feeding tube, n = 105 49 46 3 0.1
Use of a solid food 70 60 10 0.2
Ketogenic formula 66 63 3 0.003
Expressed breast milk 8 7 1 0.9
AE or abnormal lab result
69 65 4 0.01
Constipation 35 35 0 0.009
Decreased HCO3− level* 36 34 2 0.2
Vomiting, reflux 22 11 11 0.7
Low free carnitine level# 9 9 0 0.3
Feeding difficulty 6 5 1 0.7
Kidney stone 3 3 0 0.5
Transient hypoglycemia 2 2 0 0.6
Others 7 7 0 0.3
AE which required a management 63 59 4 0.1
Table 4. Differences between the patients who continued to be on the KD and the patients who withdrew early 
before they completed the 3 months of the KD therapy. KD, ketogenic diet; SD, standard deviation; N, number; 
AE, adverse event; KD. *Decreased HCO3- level (<18 mEq/L). #Low free carnitine level (<27 µmol/L).
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Restricting the diet or measuring the amount can be more difficult for the parents during this period. Our data 
regarding the selected food options supports this finding in which a bigger variation was reported among children 
aged between 1 and 2 years old in comparison to the other two age groups in which one type of foods (solid vs. 
liquid) were predominantly used (p = 0.001).
Patient growth data were not included. Some studies have reported osteopenia, growth arrest and weight loss 
in children on the KD25,26. It would be beneficial to learn how to address these issues in a more focused manner 
in the infant period, however, they may be more properly addressed in a long-term evaluation in collaboration 
with an endocrinologist. At present, the role of ketosis during the diet remains unknown. In our study, potential 
relationships between ketosis and seizure frequency or withdrawal from the KD was not evaluated. Technical 
limitation: urine ketones positive for most of the patients. Additionally, because of the retrospective nature of 
the study, it was difficult to identify the temporal relationship between urine ketones and seizure reduction. A 
recent study demonstrated the inconsistent relationship between ketosis and good seizure control in infants12,13. 
The fidelity of this relationship could be addressed in a future study. Lastly, the context in which this study was 
completed - a comprehensive epilepsy center with two dietitians working exclusively on the KD – may have low-
ered the rate of early withdrawal. On the other hand, because of a high volume of referrals for intractable epilepsy, 
we may have selectively included children with the most severe forms of epilepsy. Despite these limitations, the 
study has clinical significance demonstrating a safe and variable use of KD in young children. These findings will 
facilitate the safe use of the diet therapy in this population.
Conclusion
The KD continues to be an effective, safe, and well tolerated treatment option for infants with intractable epilepsy. 
Tolerability may be enhanced by using a liquid-based diet in this age group, the role of expressed breast milk 
in which should be further elaborated. The availability of new diagnostic studies such as genetic testing could 
promote early and effective use of the KD by identifying patients who might favorably respond to the KD. Future 
studies with larger patient sample sizes require multi-center collaboration and would further refine our under-
standing of which genetic abnormalities and epilepsy syndromes respond best to the ketogenic diet.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author upon reasonable request.
Total
<1year 
old
1–2 year 
old
>2 year 
old P-value
N 109 44 38 27
Female 59 23 23 13 0.6
West syndrome 60 28 24 8 0.0009
Outcome at 3 months
Seizure free 20 10 6 4 0.6
>90% reduction 3 2 0 1
50–90% reduction 19 8 4 7
<50% reduction 55 21 21 13
Discontinuation before 3mo 12 3 7 2 0.2
Improved cognition per parent, n = 95 47 23 14 10 0.4
High KD ratio ≥ 4:1 71 37 18 16 0.001
Tube-fed 49 23 17 9 0.4
Expressed breast milk 8 8 0 0 0.002
Food type, n = 104
Solid 35 4 17 14 <0.0001
Liquid 34 16 11 7
Solid and liquid 35 22 10 3
Ketogenic formula, n = 104 66 37 20 9 <0.0001
AE or abnormal lab results
69 30 25 14 0.6
Constipation 35 22 9 4 0.005
Decreased HCO3− level
36 18 9 9 0.2
Vomiting, reflux 12 5 5 2 0.8
Low free carnitine level
9 4 5 0 0.07
Feeding difficulty 6 0 3 3 0.08
Kidney stone 3 3 0 0 0.07
Transient hypoglycemia
2 1 1 0 0.7
Others 7 5 2 0 0.2
AE which required a management 63 29 23 11 0.01
Table 5. Age-related differences. AE, adverse event; KD, ketogenic diet. *Decreased HCO3- level (<18 mEq/L). 
Low free carnitine level (<27 µmol/L).
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